The stock of Roivant Sciences Ltd. (NASDAQ:ROIV) increased by $0.14 on Monday to finish at $11.71, up 1.21 percent. The last five days have seen an average of 3,314,740 shares of common stock traded. 13 times new highs were reached in the current year, with a gain of $3.72. The average number of shares traded over the last 20 days was 3,126,090, while the average volume over the last 50 days totaled 5,394,970.
ROIV stock appreciated 0.34% since last month. On 07/24/23, the company’s shares reached a one-month low of $10.56. The stock touched a high of $12.01 on 07/18/23, after rallying from a low of $2.87 in 52 weeks. The price of ROIV stock has risen by 46.56% or $3.72 this year, reaching a new high 13 times. Still, the stock price is down -2.46% from the 52-week high.
Insider Transactions
ROIV stock investors should be aware that Roivant Sciences Ltd. (ROIV) stock had its last reported insider trading activity 12 days ago on Aug 03. On Aug 03, Chief Operating Officer Venker Eric sold 44,629 shares at $11.93 each. This transaction resulted in the insider making $532,424. On Aug 03, Kumar Rakhi sold 3,681 shares at a price of US$12.00. After the transaction, the insider now owns 199,328 shares. Chief Operating Officer Venker Eric had earlier sold 16,397 shares on Aug 02 for $11.86 a share. The transaction was completed for $194,468.
Valuation Metrics
Beta for the stock is 1.28. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 144.49, the price-to-book (PB) ratio of 7.23.
Financial Health
For the three months ended March 30, Roivant Sciences Ltd.’s quick ratio was 6.60, while its current ratio was 6.60, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending March 30 is 0.32, and the total debt to equity ratio is 0.36. As far as profitability goes, gross margin for the trailing twelve months is 78.60% percent. Based on annual data, it had gross profit of $48.15 million and revenue of $61.28 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ROIV’s return on assets (ROA) during the last 12 months has been -42.90%. There was a -72.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -86.60%.
Earnings Surprise
According to Roivant Sciences Ltd.’s quarterly financial report for the quarter that ended March 30. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $27.38 million, while revenues rose by 38.06% to $17.05 million. It was predicted that Roivant Sciences Ltd.’s quarterly earnings would be -$0.2, but it ended up being -$0.36, beating the consensus by 44.40%. EBITDA was -$228.21 million for the quarter. Equity owned by shareholders amounts to $766.81 million.
Technical Picture
Here’s a quick look at Roivant Sciences Ltd.’s (ROIV) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 60.11%, suggesting the stock is Neutral, with a 26.51% historical volatility rate.
The stochastic %K and %D were 67.87% and 60.52% respectively, while the average true range (ATR) was 0.48. Based on the 14-day stochastic reading of 77.17%, the RSI (14) reading is 59.31%. On the 9-day MACD Oscillator, the stock is at 0.06, and the 14-day reading is at 0.07.
Analyst Ratings
In its analyst report released on June 08, 2023, BofA Securities began covering Roivant Sciences Ltd. (NASDAQ: ROIV). The stock was rated as a Neutral by the brokerage firm. Analysts have assigned Roivant Sciences Ltd. (ROIV) an Buy rating. ROIV is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 8 others recommend it as a buy.
What is ROIV’s price target for the next 12 months?
The current consensus forecast for the stock is between $12.00 and $23.00, with a median target price of $15.00. In analyzing these forecasts, the average price target given by analysts for Roivant Sciences Ltd. (ROIV) is $15.88.
